Insider trades
Matthew T. Wiley, Chief Officer of Definium Therapeutics DFTX, has filed 0 purchases and 6 sales on the open market. Over the past 12 months that comes to a net sale of $242.4K. The latest trade was on 09/25.
Matthew T. Wiley
Chief Commercial Officer
- Company
- Definium Therapeutics DFTX
- First filing
- 23/03/16
- Trades
- 20 trades
- Buys / sales
- 0 / 6
- 12-month net buying
- −$242.4K
- Last trade
- 09/25
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale10b5-1 plan | 09/25 | 09/29 | 3,097 sh | $36.57 | $113,257.29 | −0.9% | |
| Open-market sale10b5-1 plan | 06/25 | 06/26 | 2,867 sh | $45.03 | $129,101.01 | −1.6% | |
BioXcel TherapeuticsBTAIQ | Open-market sale10b5-1 plan | 24/10/03 | 24/10/03 | 6,272 sh | $0.55 | $3,449.6 | −24.8% |
BioXcel TherapeuticsBTAIQ | Open-market sale10b5-1 plan | 24/09/16 | 24/09/17 | 215 sh | $0.69 | $148.35 | −5.1% |
BioXcel TherapeuticsBTAIQ | Open-market sale10b5-1 plan | 24/06/17 | 24/06/18 | 244 sh | $1.26 | $307.44 | −6.5% |
BioXcel TherapeuticsBTAIQ | Open-market sale10b5-1 plan | 24/04/04 | 24/04/08 | 1,008 sh | $2.64 | $2,661.12 | −25.2% |
